The importance of efficacy and partial agonism in evaluating models of B lymphocyte activation.
Immunologists have developed a range of in vitro techniques for probing the receptor mediated response of cells comprising the immune system. An important and ubiquitous method is the use of antibodies in either soluble or aggregated form to engage cell surface receptors and transmit a signal. Models of cell and molecular interactions, derived from the use of these antibodies, form the basis of our efforts to understand and explain the corresponding in vivo systems. However, interpreting in vitro experiments and distinguishing between alternative models is difficult. This complexity is illustrated here using B cell stimulation by surface immunoglobulin and CD40. The fluorescent cell labelling dye carboxyfluorescein, diacetate, succinimidyl ester (CFSE) is used to show that many anti-Ig and CD40 stimulatory agents, used to assess the role of B cells and lymphokines, are partial agonists. By modelling each step in B cell signalling, activation and division it is possible to show that small changes in signal contributed by a second receptor can generate numerous distinct dose response curves that are highly dependent on the "efficacy" of signal transmission by the primary ligand and the number of cell divisions taken in culture. Differences in dose response curves become particularly striking if the primary activating stimulus is a partial agonist. Although exemplified here with B cell stimulation the conclusions are applicable to other in vitro activation systems and suggest ways to improve both the design and interpretation of in vitro experiments.
Hodgkin
P D
PD
Medical Foundation of the University of Sydney, Centenary Institute for Cancer Medicine and Cell Biology, Newtown, Australia. p.hodgkin@centenary.usyd.edu.au
Chin
S H
SH
Bartell
G
G
Mamchak
A
A
Doherty
K
K
Lyons
A B
AB
Hasbold
J
J
D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology*; D002455:Cell Division; D002478:Cells, Cultured; D006801:Humans; D017578:Immunoglobulin Class Switching; D015847:Interleukin-4 / Q000494:pharmacology; D008213:Lymphocyte Activation; D008954:Models, Biological
D015847:Interleukin-4